Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22 / CD40

Blood (2025) 146 (26): 3228–3233.

https://doi.org/10.1182/blood.2025028489

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Retrospective evaluation of the G8 score in CLL patients treated with targeted therapies: A single-center experience

Alessandro Sanna, Chiara Maria Rapolla, Gabriella Carlomagno, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 2116.

https://doi.org/10.1182/blood-2025-2116

Published: 2025

Journal Articles

Mutational architecture and clonal heterogeneity in myelofibrosis: Prognostic role of variant type and acquisition sequence

Fiorenza Vanderwert, Valentina Boldrini, Camilla Ghetti, Alessio Enderti, Danilo Tarantino, Giada Rotunno, Elena Nacca, Giulia Borgi, Lorenzo Fagiolo, Giulio Capecchi, Alessandro Vannucchi, Paola Guglielmelli

Blood (2025) 146 (Supplement 1): 3760.

https://doi.org/10.1182/blood-2025-3760

Published: 2025

Journal Articles

Clonal architecture inferred from routine NGS data predicts outcome and response to JAK-inhibitors in myelofibrosis

Valentina Boldrini, Alessio Enderti, Fiorenza Irushani Vanderwert, Camilla Ghetti, Giuseppe Gaetano Loscocco, Giulio Capecchi, Giacomo Coltro, Carmela Basile, Lucrezia Morrone, Luca Guarnera, Luca Maurillo, Maria Teresa Voso, Emilia Scalzulli, Massimo Breccia, Alessandro Vannucchi, Paola Guglielmelli

Blood (2025) 146 (Supplement 1): 3753.

https://doi.org/10.1182/blood-2025-3753

Published: 2025

Journal Articles

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Paola Guglielmelli, Francesca Crupi, Mirko Lomi, Francesco Mannelli, Jessica Caroprese, Niccolò Bartalucci, Stefano Soddu, Chiara Maccari, Alessio Enderti, Daniele Colazzo, leonardo Signori, Giada Rotunno, Alfonso Piciocchi, Giuseppe Gaetano Loscocco, Sara Bianchini, Elena Nacca, Paola Fazi, Marco Vignetti, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2025-3751

Published: 2025

Journal Articles

Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics

Blood (2025) 146 (Supplement 1): 3750.

https://doi.org/10.1182/blood-2025-3750

Published: 2025

Journal Articles

Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients

Blood (2025) 146 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2025-1026

Published: 2025

Journal Articles

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2025-1025

Published: 2025

Journal Articles

DIPSS-R: A revised age-agnostic clinical risk model for chronic phase primary myelofibrosis

Ayalew Tefferi, Alessandro Vannucchi, Yassin Bashir, Ahmed Abdelrheem, Maymona Abdelmagid, Giuseppe Gaetano Loscocco, leonardo Signori, Giulia Borgi, Valentina Boldrini, Kebede Begna, Kaaren Reichard, Rong He, Cinthya Mendoza, Tiziano Barbui, Francesco Passamonti, Animesh Pardanani, Naseema Gangat, Paola Guglielmelli

Blood (2025) 146 (Supplement 1): 84.

https://doi.org/10.1182/blood-2025-84

Published: 2025

Journal Articles

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Blood (2025) 146 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2025-5243

Published: 2025

Journal Articles

Single-cell multi-omics profiling reveals distinct patterns of clonal expansion and microenvironmental shifts associated with disease evolution in patients with Myelodysplastic Syndromes

Matteo Zampini, Elena Riva, Nicolas Sompairac, Giulia Maggioni, Rita Antunes Dos Reis, Rosa Andres Ejarque, Laura Crisafulli, Nicolas Derus, Martina Tarozzi, Claudia Sala, Pamela Acha, Emili Cid Roldós, Elisabetta Sauta, Luca Lanino, Alessia Campagna, Gabriele Todisco, Marta Ubezio, Antonio Russo, Francesco Pesce, Mattia Delleani, Gianluca Asti, Denise Ventura, Cristina Astrid Tentori, Alessandro Buizza, Ivan Ferrari, Matteo Brindisi, Nicole Pinocchio, Elisa Calvetti, Nicla Manes, Chiara Milanesi, Mara Memoli, Federico Caretti, Rongrong Xie, Lorea Chaparro, Caterina Mata, Armando Santoro, Valeria Santini, Amer Zeidan, Rami Komrokji, Paola Guglielmelli, Alessandro Vannucchi, Guillermo Garcia-Manero, Simona Colla, Saverio D'Amico, Guido Sanguinetti, Gastone Castellani, Francesc Sole, Shahram Kordasti, Francesca Ficara, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3830.

https://doi.org/10.1182/blood-2025-3830

Published: 2025

Journal Articles

Trial in progress: Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN-PV)

Alessandro Rambaldi, John Mascarenhas, Paolo Bettica, Maurizio Caserini, Javier Suarez-Almarza, Lucia Zanetta, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 3828.

https://doi.org/10.1182/blood-2025-3828

Published: 2025

Journal Articles

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Blood (2025) 146 (Supplement 1): 3798.

https://doi.org/10.1182/blood-2025-3798

Published: 2025

Journal Articles

Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)

Alessandro Vannucchi, Chiara Paoli, Paola Guglielmelli, Michael Lahn, Giusy Di Conza, Tracey Hammett, Paramjit Kaur, Jasson Villarreal Hernandez, Mario Tiribelli, Armando Santoro, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3797.

https://doi.org/10.1182/blood-2025-3797

Published: 2025

Journal Articles

The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAK inhibitor-refractory/resistant patients with myelofibrosis

Manjola Balliu, Valentina Boldrini, Chiara Maccari, Daniele Colazzo, Ilaria Sestini, Giusy Di Conza, Michael Lahn, Paola Guglielmelli, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 5529.

https://doi.org/10.1182/blood-2025-5529

Published: 2025

Journal Articles

Changes in neutrophil-to-lymphocyte ratio (NLR) in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency (VAF)

Chiara Paoli, Paola Guglielmelli, Giulia Borgi, Lorenzo Fagiolo, Sara Bianchini, Giuseppe Gaetano Loscocco, Francesca Gesullo, Fernanda Di vaio, Cecilia Matteoli, Fabiana Pancani, Sofia Danesi, Simona Pestelli, Tiziano Barbui, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 5527.

https://doi.org/10.1182/blood-2025-5527

Published: 2025

Journal Articles

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Vikas Gupta, Yizhe Chen, Patrick Brown, Danny Jeyaraju, Moshe Talpaz, Ruben Mesa, Richard Pilot, Christopher Hernandez, Jia Wang, Jean-Jacques Kiladjian, Alessandro Vannucchi, Claire Harrison

Blood (2024) 144 (Supplement 1): 6623.

https://doi.org/10.1182/blood-2024-194223

Published: 2024

Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Haifa Kathrin Al-Ali, Claire Harrison, Ruben Mesa, Moshe Talpaz, Blanca Xicoy, Francesco Passamonti, Alessandro Vannucchi, Patrick Brown, Christopher Hernandez, Jia Wang, Jun He, Jean-Jacques Kiladjian

Blood (2024) 144 (Supplement 1): 482.

https://doi.org/10.1182/blood-2024-193645

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22 / CD40

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Retrospective evaluation of the G8 score in CLL patients treated with targeted therapies: A single-center experience

Mutational architecture and clonal heterogeneity in myelofibrosis: Prognostic role of variant type and acquisition sequence

Clonal architecture inferred from routine NGS data predicts outcome and response to JAK-inhibitors in myelofibrosis

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics

Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

DIPSS-R: A revised age-agnostic clinical risk model for chronic phase primary myelofibrosis

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Single-cell multi-omics profiling reveals distinct patterns of clonal expansion and microenvironmental shifts associated with disease evolution in patients with Myelodysplastic Syndromes

Trial in progress: Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN-PV)

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)

The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAK inhibitor-refractory/resistant patients with myelofibrosis

Changes in neutrophil-to-lymphocyte ratio (NLR) in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency (VAF)

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only